title: Haploidentical hematopoietic transplantation: current status and future perspectives.
abstract: For patients with hematologic malignancies at high risk of relapse who do not have matched donors, a suitable alternative stem cell source is the HLA-haploidentical 2 or 3-loci mismatched family donor who is readily available for nearly all patients. Transplantation across the major HLA barrier is associated with strong T-cell alloreactions, which were originally manifested as a high incidence of severe GVHD and graft rejection. The present review shows how these obstacles to successful transplantation were overcome in the last 15 years, making full haplotype-mismatched transplantation a clinical reality that provides similar outcomes to transplantation from matched unrelated donors. The review also discusses the advantages and drawbacks of current options for full haplotype-mismatched transplantation and highlights innovative approaches for re-building immunity after transplantation and improving survival.
authors.affiliation: Department of Immunology, Weizmann Institute of Science, Rehovot, Israel. yair.reisner@weizmann.ac.il
authors.forename: Yair
authors.initials: Y
authors.lastname: Reisner
authors.forename: David
authors.initials: D
authors.lastname: Hagin
authors.forename: Massimo F
authors.initials: MF
authors.lastname: Martelli
mesh_terms: D006239:Haplotypes; D019337:Hematologic Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006648:Histocompatibility / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D014181:Transplantation Immunology / Q000235:genetics* / Q000276:immunology*